肾移植受者中抗SARS-CoV-2变体单克隆抗体的中和效力 - Suppr

and Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients.

作者信息

Benotmane Ilies, Jungbauer-Groznica Martin, Staropoli Isabelle, Planas Delphine, Dehan Océane, Brisebarre Angela, Simon-Loriere Etienne, Fafi-Kremer Samira, Schwartz Olivier, Bruel Timothée, Caillard Sophie

机构信息

Department of Nephrology Dialysis and Transplantation, Strasbourg University Hospital, Strasbourg, France.

Institut national de la santé et de la recherche médicale (Inserm) UMR S1109, LabEx Transplantex, Fédération de médecine translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

出版信息

Transpl Int. 2024 Jul 16;37:13272. doi: 10.3389/ti.2024.13272. eCollection 2024.

DOI:10.3389/ti.2024.13272

PMID:39081903

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11286486/

Abstract

摘要

相似文献

and Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients.

Transpl Int. 2024 Jul 16;37:13272. doi: 10.3389/ti.2024.13272. eCollection 2024.

CoronaVac-vaccinated kidney transplant recipients with hybrid immunity have strong neutralizing responses against Omicron and Mu variants of SARS-CoV-2.

Braz J Microbiol. 2024 Dec;55(4):3303-3308. doi: 10.1007/s42770-024-01507-7. Epub 2024 Sep 10.

Enhanced SARS-CoV-2 BA.2.86 Neutralization After BA.5 Infection in Vaccinated Kidney Transplant Recipients.

Transplant Proc. 2025 Jul-Aug;57(6):1013-1017. doi: 10.1016/j.transproceed.2025.05.021. Epub 2025 Jun 28.

Decline and loss of anti-SARS-CoV-2 antibodies in kidney transplant recipients in the 6 months following SARS-CoV-2 infection.

Kidney Int. 2021 Feb;99(2):486-488. doi: 10.1016/j.kint.2020.12.001.

Neutralizing antibody responses and cellular responses against SARS-CoV-2 Omicron subvariants after mRNA SARS-CoV-2 vaccination in kidney transplant recipients.

Sci Rep. 2024 May 28;14(1):12176. doi: 10.1038/s41598-024-63147-z.

A third COVID-19 vaccine dose in kidney transplant recipients induces antibody response to vaccine and Omicron variants but shows limited Ig subclass switching.

Microbiol Spectr. 2025 Mar 4;13(3):e0219024. doi: 10.1128/spectrum.02190-24. Epub 2025 Jan 31.

Comparison of immune responses to SARS-CoV-2 spike following Omicron infection or Omicron BA.4/5 vaccination in kidney transplant recipients.

Front Immunol. 2025 Jan 14;15:1476294. doi: 10.3389/fimmu.2024.1476294. eCollection 2024.

Neutralizing Antibody and T-Cell Spike Targeted Responses Following Receipt of a Monovalent Omicron JN.1-Adapted mRNA COVID-19 Vaccine in Immunosuppressed and Healthy Individuals.

J Med Virol. 2025 Jun;97(6):e70463. doi: 10.1002/jmv.70463.

Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.

Virol J. 2024 Jun 13;21(1):138. doi: 10.1186/s12985-024-02410-1.

Attenuated neutralization, maintained specificity: Humoral response to SARS-CoV-2 booster in kidney allograft recipients.

Diagn Microbiol Infect Dis. 2025 Jan;111(1):116550. doi: 10.1016/j.diagmicrobio.2024.116550. Epub 2024 Oct 16.

本文引用的文献

SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.

Cell Rep Med. 2024 Mar 19;5(3):101474. doi: 10.1016/j.xcrm.2024.101474.

Sotrovimab therapy elicits antiviral activities against Omicron BQ.1.1 and XBB.1.5 in sera of immunocompromised patients.

Med. 2023 Oct 13;4(10):664-667. doi: 10.1016/j.medj.2023.07.007.

Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.

Lancet Infect Dis. 2023 Nov;23(11):e460-e461. doi: 10.1016/S1473-3099(23)00575-3. Epub 2023 Sep 18.

Safety, Virology, Pharmacokinetics, and Clinical Experience of High-Dose Intravenous Sotrovimab for the Treatment of Mild to Moderate COVID-19: An Open-Label Clinical Trial.

Open Forum Infect Dis. 2023 Jul 10;10(7):ofad344. doi: 10.1093/ofid/ofad344. eCollection 2023 Jul.

Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration.

Nat Commun. 2023 Jun 17;14(1):3605. doi: 10.1038/s41467-023-39292-w.

Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers.

Sci Transl Med. 2023 Mar 22;15(688):eadg2783. doi: 10.1126/scitranslmed.adg2783.

Kidney Transplant and Dialysis Patients Remain at Increased Risk for Succumbing to COVID-19.

Transplantation. 2023 May 1;107(5):1136-1138. doi: 10.1097/TP.0000000000004462. Epub 2023 Apr 22.

Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave.

Am J Transplant. 2022 Dec;22(12):3130-3136. doi: 10.1111/ajt.17128. Epub 2022 Jul 1.

Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge.

Transplantation. 2022 Aug 1;106(8):1528-1537. doi: 10.1097/TP.0000000000004200. Epub 2022 Jul 22.

Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients.

Sci Transl Med. 2022 Mar 16;14(636):eabl6141. doi: 10.1126/scitranslmed.abl6141.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

and Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献